In addition, companies share development costs associated with specific global and U.S. studies, ranging from 55% (Incyte) to 45% (MorphoSys); Incyte covers 100% of future development costs for trials specific to former U.S. studies. country. Parsaclisib parsaclisib (INCB50465) is a highly selective and powerful inhibitor of the phosphatidylinositol 3 kinase (PI3K) delta. PI3K is an important goal involved in malignant B cell growth, survival and proliferation, and its inhibition has the potential as a treatment mechanism for hematological malignancies and a variety of diseases transmitted and propelled by B antibodies beyond oncology. The Clinical Investigation of TArgeted PI3K-DELta Inhibition in Lymphomas (CITADEL) clinical program is currently evaluating parsaclisib in several ongoing Phase 2 studies as a treatment for non-Hodgkin lymphomas (follicular, peripheral and mantle cell). Parsaclisib is also studied in patients with autoimmune hemolytic anemia and as part of a combined treatment for patients with myelolateral neoplasms and non-Hodgkin lymphomas, including large-scale diffuse B cell lymphoma. Incyte`s shares lost 5.2% compared to the sector`s 1.7% decline compared to the previous year.
About MorphoSys MorphoSys (FSE – NASDAQ: MOR) is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of exceptional innovative therapies for patients with serious illnesses. The focus is on cancer. MorphoSys has developed with its partners through its leading expertise in antibody, protein and peptide technologies and has contributed to the development of more than 100 candidates, 28 of whom are currently in clinical development. In 2017, Tremfya (R), marketed by Janssen for the treatment of plaque psoriasis, became the first drug based on MorphoSys antibody technology to obtain regulatory approval. Tafasitamab (MOR208), the company`s most advanced proprietary candidate, has been named after the U.S. FDA for a revolutionary treatment for the treatment of patients with relapsed/refractory lymphatic lymphoma (DLBCL). The MorphoSys Group, headquartered near Munich, employs approximately 405 people, including the Munich-based U.S. subsidiary MorphoSys US Inc. For more information, see www.morphosys.com.
Tafasitamab is clinically studied as a therapeutic option for B cell malignositities in a series of ongoing combined studies. An open-stage 2 study (L-MIND study) examines the safety and efficacy of tafasitamab in combination with lenalidomide in patients with R/R DLBCL who are not eligible for high-dose chemotherapy (HDC) and autologous stem cell transplantation (ASCT). The ongoing Phase 3 B-MIND study evaluates the association of tafasitamab and bendamustine with rituximab and bendamustine in r/r DLBCL. In addition, tafasitamab is currently being studied in patients with RLL/SLL after discontinuing prior treatment with Bruton tyrosine kinase (BTK) in combination with idelalisib or venetoclax.